These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Immunohistochemical study of the predictive value of oncoproteins p53, HER-2 and c-myc during radiotherapy for squamous cell carcinoma of the cervix].
    Author: Gasparian NA, Pozharisskiĭ KM, Zharinov GM, Vinokurov VL, Kuznetsova ME, Neklasova NIu.
    Journal: Vopr Onkol; 2007; 53(4):439-44. PubMed ID: 17969407.
    Abstract:
    Out of 80 patients with squamous cell cervical carcinoma (stage II-III), p53 expression was observed in 30% of tumors prior to treatment and 49% in the course of radiotherapy. A correlation between degree of p53 expression before treatment, on the one hand, and overall and recurrence-free survival, on the other, was identified: high expression of mutated gene-suppressor p53 was 53% while for absence or low expression, it rose to 67% (p=0.03). For overexpression, 20-month survival was 65%; absence--81% (p=0.01). Hence, p53 expression may be used as a predictive factor in radiotherapy for cervical carcinoma. No correlation was found between p53 expression, on the one hand, and such basal clinico-morphological parameters as stage, morphological pattern and tumor cell differentiation, on the other. HER2(3t) overexpression occurred in 2 (2.5%) which seems to point to its insignificant role in squamous cell cervical carcinoma. There was no relationship between c-myc expression and long-term results.
    [Abstract] [Full Text] [Related] [New Search]